Summary
Global Markets Direct’s, ‘Aeterna Zentaris Inc. - Product Pipeline Review - 2016’, provides an overview of the Aeterna Zentaris Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Aeterna Zentaris Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Aeterna Zentaris Inc.
- The report provides overview of Aeterna Zentaris Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Aeterna Zentaris Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Aeterna Zentaris Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Aeterna Zentaris Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Aeterna Zentaris Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aeterna Zentaris Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Aeterna Zentaris Inc. Snapshot 6
Aeterna Zentaris Inc. Overview 6
Key Information 6
Key Facts 6
Aeterna Zentaris Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Aeterna Zentaris Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Aeterna Zentaris Inc. - Pipeline Products Glance 14
Aeterna Zentaris Inc. - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Aeterna Zentaris Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Aeterna Zentaris Inc. - Early Stage Pipeline Products 16
IND/CTA Filed Products/Combination Treatment Modalities 16
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Aeterna Zentaris Inc. - Drug Profiles 19
zoptarelin doxorubicin 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
macimorelin acetate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ozarelix 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AEZS-120 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AEZS-124 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AEZS-125 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AEZS-126 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AEZS-134 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AEZS-138 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AEZS-140 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules for Undisclosed Indication 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Aeterna Zentaris Inc. - Pipeline Analysis 34
Aeterna Zentaris Inc. - Pipeline Products by Target 34
Aeterna Zentaris Inc. - Pipeline Products by Route of Administration 35
Aeterna Zentaris Inc. - Pipeline Products by Molecule Type 36
Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action 37
Aeterna Zentaris Inc. - Recent Pipeline Updates 38
Aeterna Zentaris Inc. - Dormant Projects 48
Aeterna Zentaris Inc. - Discontinued Pipeline Products 49
Discontinued Pipeline Product Profiles 49
AEZS-115 49
AEZS-123 49
AEZS-131 49
AEZS-132 50
AN-215 50
AN-238 50
perifosine 50
teverelix 50
Aeterna Zentaris Inc. - Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53
List of Tables
Aeterna Zentaris Inc., Key Information 6
Aeterna Zentaris Inc., Key Facts 6
Aeterna Zentaris Inc. - Pipeline by Indication, 2016 9
Aeterna Zentaris Inc. - Pipeline by Stage of Development, 2016 10
Aeterna Zentaris Inc. - Monotherapy Products in Pipeline, 2016 11
Aeterna Zentaris Inc. - Out-Licensed Products in Pipeline, 2016 12
Aeterna Zentaris Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Aeterna Zentaris Inc. - Phase III, 2016 14
Aeterna Zentaris Inc. - Phase II, 2016 15
Aeterna Zentaris Inc. - IND/CTA Filed, 2016 16
Aeterna Zentaris Inc. - Preclinical, 2016 17
Aeterna Zentaris Inc. - Discovery, 2016 18
Aeterna Zentaris Inc. - Pipeline by Target, 2016 34
Aeterna Zentaris Inc. - Pipeline by Route of Administration, 2016 35
Aeterna Zentaris Inc. - Pipeline by Molecule Type, 2016 36
Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action, 2016 37
Aeterna Zentaris Inc. - Recent Pipeline Updates, 2016 38
Aeterna Zentaris Inc. - Dormant Developmental Projects,2016 48
Aeterna Zentaris Inc. - Discontinued Pipeline Products, 2016 49
Aeterna Zentaris Inc., Subsidiaries 51
List of Figures
Aeterna Zentaris Inc. - Pipeline by Top 10 Indication, 2016 8
Aeterna Zentaris Inc. - Pipeline by Stage of Development, 2016 10
Aeterna Zentaris Inc. - Monotherapy Products in Pipeline, 2016 11
Aeterna Zentaris Inc. - Out-Licensed Products in Pipeline, 2016 12
Aeterna Zentaris Inc. - Pipeline by Top 10 Target, 2016 34
Aeterna Zentaris Inc. - Pipeline by Route of Administration, 2016 35
Aeterna Zentaris Inc. - Pipeline by Molecule Type, 2016 36
Aeterna Zentaris Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 37
